On secondary prevention of pulmonary embolism recurrences
Abstract
Based upon 102 clinical observations, the authors have studied the capability of sulodexide to conduct secondary prevention of recurrences of pulmonary embolism, compared to the standard methods of prescribing indirect anticoagulants (warfarin). Introduction of sulodexide proved to have considerable efficiency to prevent recurrences of the disease, and was associated with a lesser quantity of haemorrhagic complications. The author draws a conclusion that sulodexide can be recommended to be used in medical practice to conduct secondary prevention of pulmonary embolism as an alternative of warfarin.
About the Authors
O. N. Krasyukova
Vladivostok State Medical University
Russian Federation
Russian Federation
I. V. Naumova
Vladivostok State Medical University
Russian Federation
Russian Federation
E. V. Kinyaikina
Vladivostok State Medical University
Russian Federation
Russian Federation
E. D. Buyakova
Primorsky Regional Clinical Hospital No. 1, Vladivostok
Russian Federation
Russian Federation
References
1. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений // Ассоциация флебологов России. Всероссийское общество хирургов. М.: Медиа Сфера, 2010. 54 с.
2. Стойко Ю.М., Замятин М.Н. Современные возможности профилактики тромбоэмболических осложнений у пациентов с высоким и очень высоким риском // Хирургия. Приложение к журналу Consilium medicum. 2007. № 2. С. 40-43.
3. Яковлев В.Б., Яковлева М.В., Венозные тромбоэмболические осложнения: диагностика, лечение, профилактика // Рос. мед. вести. 2002. № 2. C.4-18.
4. Adiguzel C., Iqbal O., Hoppenstead D. et al. Сomparative anticoagulant and platelet modulatory effects of Enoxaparin and Sulodexide // Clinical and Applied Thrombosis // Hemostasis. 2009. Vol. 15. No. 5. P. 501-511.
5. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines 8th Ed // Chest. 2008. Vol. 133, Suppl. 6 P. 160-198.
6. Callas D.D., Hoppensteadt D.A., Jeske W et al. Comparative pharmacologic profile of a glycosaminoglycan mixture, sulodexide, and a chemically modified heparin derivative, suleparoide // Semin. Thromb. Hemost. 1993.Vol.19, suppl. 1. P. 49-57.
7. Errichi B.M, Cesarone B.M., Belcaro G. Prevention of reccurent deep vein thrombosis with Sulodexide: the sanval registry // Angiology 2004. Vol. 55. No. 3. Р 243-249.
8. Garcia D.A., Regan S., Crowther M. et al. The risk of hemorrhage among patients with Warfarin-associated coagulopathy // Journal of the American College of Cardiology. 2006. Vol. 47. P. 804-808.
9. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide // Med. Res. Rev. 1998. Vol. 18. P. 1-20.
10. Heit J.A. Venous thromboembolism epidemiology: implications for prevention and management // Semin. Thromb. Hemost. 2002. Vol. 28, suppl. 2. P. 3-13.
11. Hoeper M.M., Mayer E., Simonneau G., Rubin L.J. Chronic thromboembolic pulmonary hypertension // Circulation. 2006. Vol. 113. P. 2011-2020.
12. Kroegel C., Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis // Respiration. 2003. Vol.70. No. 1. P. 7-30.
13. Lasierra C.J., Coronel G.P. et al. A study on the safety, efficacy and efficiency of Sulodexide compared with Acenocoumaroi in secondary prophylaxis in patients with deep venous thrombosis // Angiology 2006. Vol. 57, No. 1. P. 53-64.
14. Lauver D.A., Lucchesi B.R. Sulodexide: a renewed interest in this glycosaminoglycan // Cardiovasc. Drug Rev. 2006. Vol. 24. P. 214-226.
15. Ofosu F.A. Pharmacological actions of sulodexide // Semin. Thromb. Hemost. 1998. Vol. 24. P. 127-138.
Review
For citations:
Krasyukova O.N., Naumova I.V., Kinyaikina E.V., Buyakova E.D. On secondary prevention of pulmonary embolism recurrences. Pacific Medical Journal. 2011;(2):48-50. (In Russ.)
Views:
239
Email this article 